Abstract

Reserpine is an irreversible inhibitor of vesicular monoamine transporter-2 (VMAT2) used to study Parkinson’s disease (PD) and screening for antiparkinsonian treatments in rodents. Recently, the repeated treatment with a low-dose of reserpine was proposed as a progressive model of PD. Rats under this treatment show progressive catalepsy behavior, oral movements and spontaneous motor activity decrement. In parallel, compared to Wistar rats, spontaneously hypertensive rats (SHR) are resistant to acute reserpine-induced oral dyskinesia. We aimed to assess whether SHR would present differential susceptibility to repeated reserpine-induced deficits in the progressive model of PD. Male Wistar and SHR rats were administered 15 subcutaneously (s.c.) injections of reserpine (0.1 mg/kg) or vehicle, every other day and motor activity was assessed by the catalepsy, oral movements and open field tests. Only reserpine-treated Wistar rats presented increased latency to step down in the catalepsy test and impaired spontaneous activity in the open field. On the other hand, there was an increase in oral movements in both reserpine-treated strains, although with reduced magnitude and latency to instauration in SHR. After a 15-day withdrawn period, both strains recovered from motor impairment, but SHR animals expressed reduced latencies to reach control levels. Finally, we performed immunohistochemistry for tyrosine hydroxylase (TH) and α-synuclein (α-syn) 48 h after the last injection or 15 days after withdrawn. Reserpine-treated animals presented a reduction in TH and an increase in α-syn immunoreactivity in the substantia nigra and dorsal striatum (dSTR), which were both recovered after 15 days of withdraw. Furthermore, SHR rats were resistant to reserpine-induced TH decrement in the substantia nigra, and presented reduced immunoreactivity to α-syn in the dSTR relative to Wistar rats, irrespective of treatment. This effect was accompanied by increase of malondaldhyde (MDA) in the striatum of reserpine-treated Wistar rats, while SHR presented reduced MDA in both control and reserpine conditions relative to Wistar strain. In conclusion, the current results show that SHR are resilient to motor and neurochemical impairments induced by the repeated low-dose reserpine protocol. These findings indicate that the neurochemical, molecular and genetic differences in the SHR strain are potential relevant targets to the study of susceptibility to PD.

Highlights

  • Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, estimated to affect 1%–2% of those older than 60 years, and 7–10 million people worldwide (Mayeux, 2003; Van Den Eeden et al, 2003)

  • The repeated administration of reserpine resulted in the progressive increase of latency to step down the bar only in the Wistar strain, and this motor impairment was restored after treatment withdrawn (Figure 1B)

  • We found that spontaneously hypertensive rats (SHR) are resistant to catalepsy, spontaneous locomotion and oral movement impairments in a reserpineinduced progressive animal model of PD

Read more

Summary

Introduction

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, estimated to affect 1%–2% of those older than 60 years, and 7–10 million people worldwide (Mayeux, 2003; Van Den Eeden et al, 2003) Most importantly, it is a disorder with progressive onset and escalating deterioration of life quality (Braak et al, 2003). The motor symptoms are the result of the progressive and irreversible loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Such loss of dopaminergic inputs concurrently progresses with the accumulation of intracellular α-synuclein (α-syn)-rich protein inclusions, known as Lewy bodies (McNaught et al, 2001; Lotharius and Brundin, 2002)

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.